Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

ACUTE MYELOID LEUKEMIA

TP53 mutation screening for patients at risk of myeloid malignancy

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: TP53-specific next generation sequencing assay validation.

Data availability

Raw sequencing data are available in the NCBI Sequence Read Archive (SRA) (Accession: PRJNA1074853).

References

  1. Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518:552–5.

    Article  CAS  PubMed  Google Scholar 

  2. Heuser M. Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment? Hematol-Am Soc Hemat. 2016;2016:24–32.

    Google Scholar 

  3. Kuzmanovic T, Patel BJ, Sanikommu SR, Nagata Y, Awada H, Kerr CM, et al. Genomics of therapy-related myeloid neoplasms. Haematologica. 2020;105:e98–e101.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kayser S, Dohner K, Krauter J, Kohne CH, Horst HA, Held G, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117:2137–45.

    Article  CAS  PubMed  Google Scholar 

  5. Lawal RA, Mukherjee D, Limerick EM, Coles W, Hsieh MM, Dillon LW, et al. Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism. Blood. 2022;140:2514–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ghannam JY, Xu X, Maric I, Dillon L, Li Y, Hsieh MM, et al. Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation. Blood. 2020;135:1185–8.

    PubMed  PubMed Central  Google Scholar 

  7. Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023;41:1265–74.

    Article  CAS  PubMed  Google Scholar 

  8. Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, et al. T-cell lymphoma and secondary primary malignancy risk after commercial CAR T-cell therapy. Nat Med. 2024;30:984–9.

    Article  CAS  PubMed  Google Scholar 

  9. Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, et al. DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. JAMA. 2023;329:745–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl J Med. 2013;368:2059–74.

    Article  Google Scholar 

  12. Samur MK, Roncador M, Samur AA, Fulciniti M, Bazarbachi AH, Szalat R, et al. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 2023;141:1724–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Diamond B, Ziccheddu B, Maclachlan K, Taylor J, Boyle E, Ossa JA, et al. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. Blood. 2023;141:2359–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Barnell EK, Skidmore ZL, Newcomer KF, Chavez M, Campbell KM, Cotto KC, et al. Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma. Blood Adv. 2023;7:236–45.

    Article  CAS  PubMed  Google Scholar 

  15. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci USA. 2012;109:14508–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was funded by the Intramural Research Program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. Sequencing was performed in the NHLBI Intramural DNA Sequencing and Genomics Core. Digital droplet PCR was performed in the NCI Intramural CCR Genomics Core.

Author information

Authors and Affiliations

Authors

Contributions

DM and RAL collected data, performed data analysis, and wrote the manuscript. CDF, CSH, and LWD designed the study, assisted in data analysis, and wrote the manuscript.

Corresponding author

Correspondence to Christopher S. Hourigan.

Ethics declarations

Competing interests

Research at the Laboratory of Myeloid Malignancies, NHLBI is supported by the Foundation of the NIH AML MRD Biomarkers Consortium. The authors declare no other competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mukherjee, D., Lawal, R.A., Fitzhugh, C.D. et al. TP53 mutation screening for patients at risk of myeloid malignancy. Leukemia (2024). https://doi.org/10.1038/s41375-024-02283-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41375-024-02283-x

Search

Quick links